Eyenovia
  • Home
  • About
    • About Eyenovia
    • Vision
    • Leadership
  • Technology
  • Pipeline
    • Eyenovia Pipeline
    • MydCombi (Mydriasis)
    • Apersure (Presbyopia)
    • MicroPine (Myopia)
  • Partners
  • Investors
  • News + Resources
    • News
    • Resource Library
  • Menu Menu
Print Friendly, PDF & Email

Myopia Control 2020–Where are we and where are we heading

Recent Posts

  • Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference September 7, 2023
  • Eyenovia Acquires U.S. Commercial Rights To APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) From Formosa Pharmaceuticals August 16, 2023
  • Eyenovia Announces First Commercial Sale of MydCombi™ August 3, 2023

Pipeline and Technology

  • MydCombi (Mydriasis)
  • Apersure (Presbyopia)
  • MicroPine (Myopia)
  • Technology

Corporate Address

Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenovia.com

Copyright © 2023 Eyenovia, Inc. All rights reserved.
  • Twitter
  • Facebook
  • LinkedIn
  • Contact
  • Safe Harbor
  • Privacy Policy
  • Terms of Use
Latanoprost with high precision, piezo-print microdose delivery for IOP low...Packaging Delivers Micro Dose
Scroll to top